efgartigimod PH20 SC + Prednisone
Phase 2/3Completed 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bullous Pemphigoid
Conditions
Bullous Pemphigoid
Trial Timeline
Jun 9, 2022 → Sep 13, 2024
NCT ID
NCT05267600About efgartigimod PH20 SC + Prednisone
efgartigimod PH20 SC + Prednisone is a phase 2/3 stage product being developed by Argenx for Bullous Pemphigoid. The current trial status is completed. This product is registered under clinical trial identifier NCT05267600. Target conditions include Bullous Pemphigoid.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05681481 | Phase 3 | Terminated |
| NCT05267600 | Phase 2/3 | Completed |
| NCT04598477 | Phase 3 | Terminated |
| NCT04598451 | Phase 3 | Completed |
Competing Products
8 competing products in Bullous Pemphigoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| QGE031 + Placebo | Novartis | Phase 2 | 52 |
| Azathioprine or Mycophenolate mofetil | Roche | Phase 2 | 52 |
| dupilumab + Matching Placebo + Oral corticosteroids (OCS) | Sanofi | Phase 2/3 | 64 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| BIV009 | Sanofi | Phase 1 | 32 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 3 | 74 |